Research programme: biosimilars - American Biosources

Drug Profile

Research programme: biosimilars - American Biosources

Latest Information Update: 23 May 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator American Biosources
  • Class Blood coagulation factors; Blood proteins; Colony-stimulating factors; Hormones; Interferons; Interleukins; Monoclonal antibodies; Vaccines
  • Mechanism of Action Colony stimulating factor stimulants; Factor IX stimulants; Factor VIII stimulants; Glucosylceramidase stimulants; Haematopoietic cell growth factor stimulants; Hormone stimulants; Immunostimulants; Immunosuppressants; Interferon alpha stimulants; Interferon beta stimulants; Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Anaemia; Endocrine disorders; Gaucher's disease; Haematological disorders; Hepatitis B; Leukaemia; Multiple sclerosis; Neutropenia; Rheumatoid arthritis

Most Recent Events

  • 14 May 2015 Platform technology for biosimilar development is available for licensing in USA (http://www.ambioinc.com/biosimilars.html)
  • 13 May 2015 Early research in Anaemia in USA (unspecified route)
  • 13 May 2015 Early research in Endocrine disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top